

Accepted Manuscript

Muscarinic receptor oligomerization

Sara Marsango, Richard J. Ward, Elisa Alvarez-Curto, Graeme Milligan

PII: S0028-3908(17)30532-4

DOI: [10.1016/j.neuropharm.2017.11.023](https://doi.org/10.1016/j.neuropharm.2017.11.023)

Reference: NP 6950

To appear in: *Neuropharmacology*


Received Date: 27 April 2017

Revised Date: 1 November 2017

Accepted Date: 13 November 2017

Please cite this article as: Marsango, S., Ward, R.J., Alvarez-Curto, E., Milligan, G., Muscarinic receptor oligomerization, *Neuropharmacology* (2017), doi: 10.1016/j.neuropharm.2017.11.023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Muscarinic receptor oligomerization**Sara Marsango, Richard J. Ward, Elisa Alvarez-Curto and Graeme Milligan**

Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ
Scotland, U.K.

Address correspondence to Sara Marsango (Sara.Marsango@glasgow.ac.uk) or Richard J. Ward (Richard.Ward@glasgow.ac.uk)

Non-Standard Abbreviations

BRET, bioluminescence resonance energy transfer; CNO, clozapine-N-oxide; EL, extracellular loop; FCS, fluorescence correlation spectroscopy; FRET, fluorescence resonance energy transfer; GMP-PNP, guanosine 5'-[β,γ -imido] triphosphate; htrFRET, homogeneous time-resolved FRET; IL, internal loop; MEU, monomeric equivalent unit; M_{1.5}R, muscarinic acetylcholine receptor; NMS, N-methylscopolamine; PI, phosphatidylinositol; QB, quantal brightness; RASSL, Receptor Activated Solely by Synthetic Ligand; RET, resonance energy transfer; RoI, region of interest; SpIDA, Spatial Intensity Distribution Analysis; SR-TPM, spectrally-resolved two-photon microscopy; TIRF, total internal reflection fluorescence microscopy; TM, transmembrane domain.

Abstract

G protein coupled receptors (GPCRs) have been classically described as monomeric entities that function by binding in a 1:1 stoichiometric ratio to both ligand and downstream signalling proteins. However, in recent years, a growing numbers of studies have supported the hypothesis that these receptors can interact to form dimers and higher order oligomers although the molecular basis for these interactions, the overall quaternary arrangements and the functional importance of the GPCR oligomerization remain topics of intense speculation.

Muscarinic acetylcholine receptors belong to class A of the GPCR family. Each muscarinic receptor subtype has its own particular distribution throughout the central and peripheral nervous systems. In the central system, muscarinic receptors regulate several sensory, cognitive, and motor functions while, in the peripheral nervous system, they are involved in the regulation of the heart rate, stimulation of glandular secretion and smooth muscle contraction. Muscarinic acetylcholine receptors have long been used as a model for the study of GPCR structure and function and to address aspects of GPCR dimerization using a broad range of approaches. In this review, the prevailing knowledge regarding the quaternary arrangement for the various muscarinic acetylcholine receptors have been summarized by discussing work ranging from initial results obtained using more traditional biochemical approaches to those obtained with more modern biophysical techniques.

Keywords

Muscarinic acetylcholine receptor; Quaternary structure; Dimerization; Oligomerization; Ligand regulation.

Introduction

Dimerization of G protein-coupled receptors (GPCRs), that is, the structural arrangement of these receptors in pairs (dimers) at the cellular plasma membrane, or within other intracellular membrane structures, and its functional significance remain controversial subjects that have been at the centre of debate for decades. Broadly speaking, at least for class A, rhodopsin-like, receptors, the GPCR monomer represents the minimal receptor functional unit (Kuzak *et al.*, 2009; Whorton *et al.*, 2007). However, it is now accepted that receptor dimers, whether homo- or hetero-dimers, not only can be detected in many cells and tissues (Ferre' *et al.*, 2014) but may play important roles in receptor ontology and function (Farran, 2017; Franco *et al.*, 2016; Gahbauer and Böckmann, 2016; Margeta-Mitrovic *et al.*; 2000, Milligan 2004, 2009 and 2013; Smith and Milligan, 2010) as they can display distinct and novel pharmacological features compared to the corresponding monomers.

GPCRs can form not only dimers but also higher-order oligomers where more than two protomers interact as a functional or structural complex, further increasing the complexity of the subject (Marsango *et al.* 2015a; Navarro *et al.* 2016; Patowary *et al.* 2013; Liste *et al.*, 2015). However, one of the caveats of many of the approaches applied to study receptor 'dimerization' is an inability of these to resolve and specify whether a detected complex is strictly dimeric or potentially oligomeric. As such the terms 'dimeric' and 'oligomeric' are often used imprecisely and without intention to specify this feature.

The visual receptor rhodopsin is possibly the clearest example of a class A GPCR demonstrated to be present as a 'dimer' in its native setting. Employing atomic force microscopy rhodopsin appears as densely packed rows of pairs of protomers in native mouse disc membranes (Liang *et al.*, 2003; Fotiadis *et al.*, 2006). Although potential caveats in interpretation of these images have been highlighted (Chabre *et al.* 2003; Suda *et al.* 2004), such studies provide strong support for the idea that, when in close proximity, the structural organization of the basic 7-transmembrane domain architecture of members of the GPCR family can allow receptor protomers to pack together to allow close association and potential direct physical interactions. This has opened new avenues for

studies of receptor function and organization related not only to the molecular structure of potential receptor dimers but also in relation to their interaction with signal transducer proteins including G proteins and arrestins (Ferre *et al.*, 2014; Navarro *et al.* 2016; Szalai *et al.*, 2012). In certain cases, principally for members of the class C, or glutamate-like, family of GPCRs, homo- or hetero-dimeric organization is a pre-requisite for function (Ferre *et al.*, 2014; Kniazeff *et al.*, 2011; Lane and Canals, 2012; Vafabakhsh *et al.*, 2015). For example, metabotropic GABA_B receptors display an absolute requirement for the co-expression of two distinct 7-transmembrane domain polypeptides (GABA_B receptor 1 (GABA_B R1) and GABA_B receptor 2 (GABA_B R2)), derived from distinct genes, to form hetero-dimers to allow the complex to reach the cell surface and act as a functional unit (Ng *et al.*, 1999, Kuner *et al.*, 1999). These GPCRs have also been found to show marked disparity in the ligand binding properties of the dimer, depending on the specific two subunits present within the complex. The function of the agonist gabapentin at hetero-dimers formed by distinct splice variants of the GABA_BR1 (GABA_BR1a /1b) with the GABA_BR2 is reportedly very different; in that at GABA_BR1a/GABA_BR2 hetero-dimers it acted as an agonist whilst it lacks activity at the GABA_BR1b/GABA_BR2 hetero-dimer (Ng *et al.*, 2001). Similar changes in ligand binding and functional properties of hetero-dimers, compared to the corresponding GPCR homo-dimers or monomers have also been reported for some class A GPCRs, for example the κ and δ opioid receptors (Jordan and Devi 1999).

Muscarinic acetylcholine receptors

The muscarinic acetylcholine receptor family consists of five members (M₁R-M₅R) and has long been established as a paradigm for the study of GPCR structure and function, as well as for the development of non-orthosteric receptor ligands. However, the high degree of similarity of the binding pocket for acetylcholine across the family members has hindered the identification of selective orthosteric ligands. As of 2016 multiple crystal structures of four of the receptor subtypes bound by various ligands have been obtained (Haga *et al.*, 2012, Kruse *et al.*, 2012, Thal *et al.*, 2016), leaving only the structure of M₅R to be determined. Consequently, details of the atomic level structures have begun to be used in structure-based drug design for the identification of subtype

selective ligands, whilst also promoting understanding of the mode of binding of various classes of allosteric modulators (Kruse *et al.*, 2014; Miao *et al.*, 2016). Continuing efforts to use such structure-based drug design is resulting in significant advances, as discussed elsewhere in this book.

Although none of the currently available crystal structures of muscarinic receptor subtypes shows a dimeric arrangement of the receptor, information inferred from the arrangements of the α -helices of the transmembrane domains and potential interaction interfaces identified from both modelling studies and comparisons with atomic level structures of other class A receptors where dimeric contacts have been observed (Geng *et al.*, 2016; Huang *et al.*, 2013; Manglik *et al.*, 2012), have been used to design rational hypotheses for the study of the molecular basis of muscarinic receptor dimerization.

Interestingly, as will be discussed later, studies on both muscarinic M₁ and M₂ receptors have suggested that these can present in multiple co-existing and interchanging states, in both transfected model cell systems and in native tissues, with some reports indicating that contacts are fleeting and may be generated by different regions of the receptor structure (Hern *et al.*, 2010; Nenasheva *et al.*, 2013). By contrast other reports suggest that these receptors exist predominantly if not exclusively as dimers (Herrick-Davis *et al.*, 2013) or even as tetramers (Pisterzi *et al.*, 2010; Redka *et al.*, 2013; Redka *et al.*, 2014; Shivnaraine *et al.*, 2016a). Defining this more clearly and assessing why different approaches appear to result in quite distinct conclusions is a key issue for further research on muscarinic receptor (and other GPCRs) dimerization. Finally, a number of studies, both theoretical and experimental, suggest that key interactions between receptor protomers are more likely to be mediated via lipid-based contacts rather than, or in addition to, direct protein-protein interactions (Gupta *et al.*, 2017). Given the long standing interest in muscarinic receptor function and pharmacology, it is hardly surprising that this family of receptors has been used as a model to address aspects of receptor dimerization using a wide range of approaches. In addition to the potential for muscarinic receptor interactions to be intrinsically dynamic, there are recent new insights into the extent to which such interactions can also be regulated by receptor expression levels and by both certain receptor ligands and other receptor-interacting molecules and toxins (Hirschberg and Schimerlik 1994; Ilien *et al.*, 2009; Alvarez-Curto *et al.*, 2010a; Hern *et al.*, 2010, Hu *et al.*, 2013,

Nenasheva *et al.*, 2013, Patowary *et al.*, 2013, Liste *et al.*, 2015; Aslanoglou *et al.*, 2015; Pediani *et al.*, 2016).

This review will examine earlier work and overlay this with results being derived from more recently adopted approaches (see **Table 1**).

The first observations suggesting that muscarinic acetylcholine receptors might be arranged in dimers and/or higher-order oligomers were based on results from radioligand binding studies (Potter *et al.*, 1991; Hirschberg and Schimerlik 1994; Wreggett and Wells, 1995). In the early 1990s, for example, the complex profile of the competition curves between [³H]NMS and various agonists to the M₂R were interpreted as reflecting the presence of two agonist binding sites (guanine nucleotide-sensitive high affinity (H) and low affinity (L) sites) located on dimeric M₂R molecules in rabbit heart and rat brain stem (Potter *et al.*, 1991). Likewise, computer simulation of the kinetics of binding of the agonist [³H]oxotremorine-M at the porcine M₂R were consistent with the receptor existing as a mixture of monomers and potentially asymmetrical dimers (with one ligand-bound protomer while the second remained unbound) in cultured cells and in porcine atrium (Hirschberg and Schimerlik 1994). This work also highlighted the impact that levels of receptor expression may have on the equilibrium between monomers and dimers and suggested a degree of cooperativity between protomers in ligand binding (Hirschberg and Schimerlik 1994). This cooperativity has been further reflected in additional studies on M₂R where binding data were interpreted in terms of cooperative interactions within receptors organized in higher-order oligomers such as homo-trimers or homo-tetramers (Wreggett and Wells, 1995). This piece of work was also one of the first to show biochemical support of the multimeric nature of the M₂R, as shown in SDS-polyacrylamide gels of purified receptors from porcine atrial tissue (Wreggett and Wells, 1995). Wells and collaborators have made extensive use of ligand binding studies to gain further insights into the pharmacological profile of M₂R (Redka *et al.*, 2013; Redka *et al.*, 2014). In competition binding studies, using [³H]NMS and seven diverse agonists, these authors observed a dispersion of affinity, indicative of two or more classes of sites (Redka *et al.*, 2013). This has traditionally been explained as the effect of the G protein on an otherwise homogeneous population of sites in studies in which the aggregation state of the M₂R was not taken

into consideration (Birdsall *et al.*, 1978; Ehlert, 1985; Berrie *et al.*, 1979). With this purpose, these authors compared two forms of the purified M₂R devoid of G protein and reconstituted as a monomer in micellar dispersion or as a tetramer in phospholipidic vesicles (Redka *et al.*, 2013). They concluded that the heterogeneity revealed by the seven agonists at the M₂R is intrinsic to the receptor tetrameric state, is independent of coupling to G protein and it is, at least in part, a consequence of the cooperativity between linked orthosteric sites (Redka *et al.*, 2013). In subsequent work designed to identify the biologically relevant form of M₂R, studies compared the ligand binding properties and the effect on the binding profile of the poorly-hydrolysed analogue of GTP, guanosine 5'-[β,γ-imido] triphosphate (GMP-PNP), on reconstituted M₂R monomers and tetramers, with muscarinic receptors present natively in sarcolemmal membranes (Redka *et al.*, 2014). They concluded that tetrameric but not monomeric forms of the M₂R resemble muscarinic receptors in such myocardial membranes and suggested that the M₂R may signal as an oligomer (Redka *et al.*, 2014).

Returning to the early 1990s, in an attempt to study the folding and assembly of GPCRs, Maggio and collaborators (Maggio *et al.*, 1993) generated two hybrid M₃R/α_{2C}-adrenergic receptors in which the first five transmembrane domains (TM) I-V of one receptor were fused to TMVI and VII of the second and *vice-versa* (Maggio *et al.*, 1993). Expression of the individual hybrids was unable to result in stimulation of phosphoinositide (PI) hydrolysis in an agonist-dependent fashion or to allow detection of either adrenergic or muscarinic radioligand binding activity (Maggio *et al.*, 1993). In contrast, co-expression of the two hybrid receptors resulted in the appearance of both muscarinic [³H]NMS and adrenergic [³H]rauwolscine binding sites and, following incubation of cells co-transfected with the two hybrid receptors the muscarinic agonist carbachol generated an increase in PI hydrolysis (Maggio *et al.*, 1993). Such 'rescue' of receptor activity was interpreted to reflect direct interactions between the two hybrid receptors forming a dimeric complex that allowed the reconstitution of functional receptor units (Maggio *et al.*, 1993). Interestingly, co-expression of short hybrid M₃R/α_{2C}-adrenergic receptors in which 196 amino acids were deleted from the internal loop 3 (IL3) prevented the reconstitution of functional receptor units, suggesting a role of the residues located in this internal loop in regulating M₃R-M₃R interactions (Maggio *et al.*, 1996).

Although these studies were consistent with the idea of a least a proportion of muscarinic receptors being present as dimers and/or oligomers, they did not provide any intrinsic evidence of a direct physical interaction between protomers. This kind of evidence was obtained sometime later when membrane preparations from rat M₃R (rM₃R) expressing cells were analysed by Western blotting under non-reducing conditions (Zeng and Wess, 1999). Such analysis showed several immunoreactive species corresponding in size to putative rM₃R monomers, dimers and oligomers. Although differential mobility in such gels is challenging to interpret and can reflect protein aggregation stemming from the preparation conditions, subsequent co-immunoprecipitation studies provided further support for the formation of non-covalently associated rM₃R dimers and oligomers expressed within transfected COS-7 cells and in rat brain membranes (Zeng and Wess, 1999). Moreover, site-directed mutagenesis studies demonstrated the importance of disulphide-bond formation between conserved cysteine residues located in the extracellular loops (EL) 2 and 3 of the rM₃R for protomer-protomer interaction (Zeng and Wess, 1999). Wess and collaborators have made extensive use of Western blot analysis in combination with cysteine substitutions and a disulfide cross-linking strategy to gain insights into mechanisms of muscarinic receptor dimerization (Hu *et al.*, 2012; Hu *et al.*, 2013). Recently, they proposed a model in which rM₃R-rM₃R protomers interact to form at least three structurally distinct dimeric species in which protomer-protomer interactions occur as part of the formation of three distinct interfaces. The first proposed dimeric interface, the TMV-TMV interface (Hu *et al.*, 2012), involves residues at the cytosolic end of TMV, the second, the TMIV-TMV-IL2 interface, involves residues in IL2, whilst the third involves residues from the carboxy-terminal helix VIII and has been designated the TMI-TMII-Helix VIII interface (Hu *et al.*, 2013). Treatment of rM₃R-expressing COS-7 cell membranes with the muscarinic agonist carbachol was indicated to be without effect on the cross-linking pattern observed using mutants in each of TMV, IL3 or IL2, supporting a hypothesis that TMV-TMV rM₃R and TMIV-TMV-IL2 rM₃R dimers form in a constitutive fashion and that these arrangements remain unchanged upon rM₃R activation. In contrast, agonist-treatment of COS-7 cell membranes expressing rM₃R-mutants within Helix VIII resulted in an increase in the efficiency of receptor cross-link formation (Hu *et al.*, 2012; Hu *et al.*, 2013).

Although approaches such as immunoblotting, cross-linking and co-immunoprecipitation have been employed to study the basis of GPCR dimerization/oligomerization, they have limitations for the study of interactions involving integral membrane proteins due to the use of non-physiological buffers and detergents that may cause either non-native aggregation or disruption of native biological interactions. Those limitations have been addressed with the development of biophysical methods based on resonance energy transfer (RET) between two molecules, known as the “donor” and “acceptor,” positioned within a restricted distance (in the region of 2 to 8 nm) and defined orientation (Alvarez-Curto *et al.*, 2010b; Ayoub *et al.*, 2010; Ayoub, 2016). These include both bioluminescence resonance energy transfer (BRET) and variants of fluorescence resonance energy transfer (FRET), and both have been widely applied to the study of protein-protein interactions and the dimerization of muscarinic receptors and other GPCRs in particular (Goin and Nathanson, 2006; McMillin *et al.*, 2011; Alvarez-Curto *et al.*, 2010a; Ciruela *et al.*, 2010; Marsango *et al.*, 2015a; Sposini *et al.*, 2015). The most significant difference between these approaches is that BRET measures energy transfer between a bioluminescent donor (most usually variants of the luciferase from *Renilla reniformis*) and a fluorescent acceptor (eYFP, GFP or other) while FRET takes place between two fluorescent proteins with overlapping emission and excitation spectra (of the donor and acceptor, respectively) after the excitation of the donor molecule by an external light source (Ciruela *et al.*, 2010). In both FRET and BRET studies, it is important to experimentally determine that the energy transfer ($E_{(RET)}$) between donor- and acceptor- tagged species exceeds the $E_{(RET)}$ between the co-expressed and unlinked donor and acceptor molecules, in order to be able to distinguish between specific oligomerization and random collisions. Moreover, the $E_{(RET)}$ between donor- and acceptor- tagged species should be compared to that from donor- and acceptor-linked to known non-interacting proteins.

An example of the use of RET techniques, in combination with molecular studies and site-directed mutagenesis was also provided by Wess and collaborators in a study in which the mechanism of homo-dimerization of the human M₃ muscarinic acetylcholine receptor (hM₃R) was assessed and protomer-protomer interfaces of dimerization mapped (McMillin *et al.*, 2011). Mutants in which selected outward, lipid-facing residues within each of the TMs were simultaneously replaced by

alanines were produced. By performing BRET assays using such mutants the authors were able to identify residues in TMs I-V and VII that impaired the ability to these variants to form dimers. The results of this study were interpreted by means of a model in which hM₃R exists as multiple, energetically favourable, homo-dimers characterized by different geometries and in which protomer-protomer interactions could occur through each of TMV-TMV, TMVI-TMVII, TMIV-TMV and TMI-TMII (McMillin *et al.*, 2011; **Figure 1**).

In broad agreement, Patowary and collaborators (2013) showed that at the cell surface of a HEK293-derived cell line the hM₃R is able to form not only homo-dimers, but also higher-order oligomers. Herein spectrally-resolved two-photon microscopy (SR-TPM) allowed mathematical fitting of the data to indicate the hM₃R as being predominantly tetrameric, with the contributing hM₃R protomers being organized in a rhombus-shaped complex. This tetrameric form was shown to be in equilibrium with dimeric species (Patowary *et al.*, 2013; **Figure 1**). This model has subsequently been supported by mutational studies in which outward facing residues of TMI, TMIV, TMV, TMVI, TMVII as well as Helix VIII were replaced with alanines and the ability of such mutants to form dimers assessed using homogeneous time-resolved FRET (htrFRET, see below for further details) (Liste *et al.*, 2015). The mutagenic strategy was based on both the earlier studies described above (McMillin *et al.*, 2011) and molecular modelling studies that took as a starting point a high resolution, inactive state, structure of rM₃R (Kruse *et al.*, 2012). Although many mutants impaired the competence to the receptor to generate effective interacting complexes, in no case were protomer-protomer interactions fully abolished (Liste *et al.*, 2015). This also suggested the potential of the hM₃R to form higher-order complexes. To define these complexes, both rhombic (Patowary *et al.*, 2013) and linear (Manglik *et al.*, 2012; Huang *et al.*, 2013) tetramer models were considered, as these were the only ones in which modelling allowed the simultaneous binding of two heterotrimeric G-proteins in their nucleotide-free form, as in the atomic level crystal structure of the β_2 -adrenoceptor complexed with nucleotide-free G α_s (Rasmussen *et al.*, 2011). However, even though both models could explain roles for TMI and Helix VIII as well as TMV and TMVI, only the rhombic-shaped tetramer was compatible with a role of TMVII in a dimer + dimer interface involving TMVI-TMVII and part of TMI (Liste *et al.*, 2015). This model generated a complex of two dimers (in which

protomer-protomer interactions occur through an interface involving residues from TMI-TMII and Helix VIII) that interact to form a dimer + dimer interface utilizing residues from TMVI-TMVII and part of TMI. Moreover, molecules of cholesterol were specifically introduced into the model in positions that had already been observed in other published class A GPCR crystal structures (Liste *et al.*, 2015). In particular, two cholesterols interacting with the extracellular side of TMVI (making a total of four molecules in the tetrameric complex) were suggested to form a buffer between the dimers and to mediate interactions of TMVI with TMVII, as well as with residues from TMI (**Figure 1**). Molecules of cholesterol in equivalent locations have been described in both the quaternary arrangements of the adenosine A_{2A} (Jaakola *et al.*, 2008) and μ -opioid receptors (Manglik *et al.*, 2012). Furthermore, these cholesterols superimposed well with those observed in the extracellular side of the TMVII of the P2Y₁₂ receptor (Zhang *et al.*, 2014). Two molecules of cholesterol were also described at the TMI- Helix VIII dimer interface positioned as observed in the crystal structure of the β_2 -adrenoceptor (Cherezov *et al.*, 2007) and serotonin 5-HT_{2B} (Wacker *et al.*, 2013) receptors. Organization of the M₂R has also been investigated using FRET-based approaches (Pisterzi *et al.*, 2010). Herein, as measured using combinations of fluorescence intensity-based microscopy and fluorescence lifetime measurements, and in accord with the ligand binding studies discussed earlier, these studies also concluded that the M₂R is present as a tetramer at the cell surface of transiently transfected CHO-S cells. Subsequently, a combination of single-particle photobleaching, FRET, dual-color fluorescence correlation and molecular dynamics produced similar conclusions that M₂R exists as a tetramer, but also suggested that each of the protomers in this arrangement is coupled to a G_i-family G protein. This conclusion produces a complex of hetero-octamers in which the adjacent protomers interact via an oligomerization interface composed of residues within TMIV and V and in which each of the protomers directly communicates with its coupled G protein and indirectly with the G protein coupled to a neighbouring protomer (Shivnaraine *et al.*, 2016a). In a parallel study, Shivnaraine and collaborators (2016b) concluded that only interactions between constituent protomers of an M₂R oligomer complex could explain the observed allosteric effects of ligand binding that are characteristic of M₂R in myocardial preparations. To monitor such allosteric interactions, the authors developed an M₂R conformation sensor at the allosteric site, based on FRET between inserted

'FIAsh' (Hoffmann *et al.*, 2010) sequences and the mCherry fluorescent protein and performed pharmacological assays involving mutants engineered to preclude intramolecular effects (Shivnaraine *et al.*, 2016b).

Aside from efforts to define dimeric interfaces taking a strictly structural perspective, RET techniques have been widely used to detect muscarinic receptor dimers in living cells. In early studies, Goin and Nathanson (2006) used BRET to demonstrate that each of M₁R, M₂R and M₃R have the ability to form both homo- and hetero-dimers that varied slightly in their interaction affinities and suggested a propensity to form homo-dimers rather than higher-order or hetero-meric complexes. Such BRET studies, however, did not allow discrimination between receptors at the cell surface and the total receptor population present within the cell. Detection of dimerization of the M₃R has, therefore, been studied in greater detail using FRET-microscopy to allow selection of specific regions of interest, for instance, within the plasma membrane (Alvarez-Curto *et al.*, 2010a, Patorwary *et al.*, 2013).

Homogeneous time-resolved FRET (htrFRET), which does not require the use of a microscope, has also been developed and extensively used in the study of GPCR oligomerization (Maurel *et al.*, 2008). Herein, specific self-labelling protein tags e.g. SNAP, CLIP or HALO tags (Alvarez-Curto *et al.* 2010a, Hussain *et al.*, 2013, Kolberg *et al.*, 2013, Aslanoglou *et al.*, 2015, Marsango *et al.*, 2015a; Marsango *et al.*, 2015b; Ward *et al.*, 2010) have been fused to (usually) the N-terminal domain of a GPCR. Covalent labelling with specific lanthanide (terbium or europium) cryptates that act as energy donor, and a compatible energy acceptor allow htrFRET. Use of non-cell permeant substrates to label the tags allows the exclusive detection of those present at the cell surface. Additionally, the long lifetime of emission from the donor lanthanide means that the signal can be recorded at times after which short-lived cellular autofluorescence has decayed (Maurel *et al.*, 2008; Alvarez-Curto *et al.* 2010a, Hussain *et al.*, 2013, Kolberg *et al.*, 2013, Aslanoglou *et al.*, 2015, Marsango *et al.*, 2015a; Marsango *et al.*, 2015b; Liste *et al.*, 2015; Ward *et al.*, 2010). As well as basal homo-dimerization of M₃R and hetero-dimerization of M₂R/M₃R at the cell surface (Alvarez-Curto *et al.*, 2010a, Aslanoglou *et al.*, 2015; Liste *et al.* 2015) potential regulation of homo-dimer and

hetero-dimers formation by ligands has also been investigated using such approaches (Alvarez-Curto *et al.*, 2010a, Aslanoglou *et al.*, 2015; Liste *et al.* 2015). To explore this Alvarez-Curto and collaborators (2011) used combinations of wild type hM₃R and a genetically engineered form of this receptor designated as a 'RASSL' (Receptor Activated Solely by Synthetic Ligand) mutant (Conklin *et al.*, 2008; Pei *et al.*, 2008; Dong *et al.*, 2010). The hM₃-RASSL receptor incorporates mutations in TMIII and TMV that render it unable to bind effectively the endogenous ligand, acetylcholine, whilst in parallel it acquire affinity for the synthetic ligand clozapine-N-oxide (CNO), (Alvarez-Curto *et al.*, 2011). Cells expressing both forms of these receptors (hM₃R + hM₃-RASSL) that were tagged with appropriate pairs of fluorescent proteins or with SNAP/CLIP tags were used to demonstrate the presence of homo-dimers (Alvarez-Curto *et al.*, 2011). Here, it was found that treatment with the agonist carbachol significantly reduced the FRET signal whilst treatment with the muscarinic antagonist atropine was without effect, suggesting that, in the presence of the agonist, the complexity of the quaternary structure of the hM₃R was reduced (Alvarez-Curto *et al.*, 2011). However, when measurements were focussed exclusively at the cell surface treatment with appropriate selective agonists (carbachol and acetylcholine for the wild type receptor and CNO for the RASSL) the oligomeric structure became more complex (Alvarez-Curto *et al.*, 2011). Once more, the antagonist atropine was without effect (Alvarez-Curto *et al.*, 2011). Whilst these results appear contradictory, conventional "imaging" FRET using pairs of fluorescent proteins monitors receptor proximity throughout the cell whereas htrFRET using the self-labelling protein tags only detected receptors at the cell surface. This may reflect genuine differences in the effects of ligands upon quaternary structure depending upon cellular location but requires further analysis. The use of htrFRET to analyse muscarinic receptor organization has been further exploited to concurrently monitor homo-dimers of hM₃-RASSL or hM₂R and hM₃-RASSL-hM₂R hetero-dimers in cell co-expressing hM₂R and hM₃R (Aslanoglou *et al.*, 2015). Here once more, atropine had no effect on the extent of dimerization, whilst the selective (in this context) hM₂R agonist, carbachol, caused an increase in level of hM₂R homo-dimerization and a reduction in the level of hM₂R-hM₃-RASSL hetero-dimerization.

Recently, to gain further insights into the dimerization of GPCRs and potential effects of ligand binding Milligan and collaborators (Ward *et al.*, 2015, Pediani *et al.*, 2016; Ward *et al.*, 2017; Marsango *et al.*, 2017) have adopted a biophysical technique, Spatial Intensity Distribution analysis (SpIDA), developed by Wiseman and co-workers (Godin *et al.*, 2011 and 2015; Barbeau *et al.*, 2013). This allows the detection of protein-protein interactions with a spatial resolution of 220 nm; a limitation which is overcome by oversampling the laser spot confocal volume and quantifying the excitation illumination volume for membrane oligomerization measurements as a surface as opposed to a 3-dimensional volume (Pediani *et al.*, 2017) Briefly, SpIDA is based upon the analysis of regions of interest (RoIs) selected within laser scanning confocal images of cells expressing the protein of interest tagged with, for example, an appropriate monomeric fluorescent protein (Godin *et al.*, 2011 and 2015; Barbeau *et al.*, 2013; Ward *et al.*, 2015; Pediani *et al.*, 2016; Ward *et al.*, 2017; Marsango *et al.*, 2017). Images are then analysed by constructing fluorescence intensity histograms for the pixels within the RoI and then applying super Poissonian distribution curves. From these, both the average quantal brightness (QB) within the RoI and also the mean fluorescent intensity of the fluorescent particles can be calculated (Godin *et al.*, 2011 and 2015; Barbeau *et al.*, 2013; Ward *et al.*, 2015; Pediani *et al.*, 2016; Ward *et al.*, 2017; Marsango *et al.*, 2017).

The normalization of such values for the QB of the fluorescent label alone (expressed in a manner which ensures that it is appropriately located in cells and is in a monomeric state) allows the determination of the quaternary structure of the tagged protein of interest (expressed as monomeric equivalent unit, MEU) and its density (expressed as particles per μm^2) (Zakrys *et al.*, 2014, Ward *et al.*, 2015, Pediani *et al.*, 2016). Thus, if a suitably tagged GPCR has a QB twice that of the label in a monomeric state, then it is likely to be a dimer.

In various studies in which the protein of interest was labelled with monomeric enhanced Green Fluorescent Protein (mEGFP) for example, the QB of the fluorescent label alone was determined by performing SpIDA measurements on the basolateral membrane of cells expressing a single mEGFP modified at the N-terminal region by incorporation of a palmitoylation + myristoylation consensus sequence (PM-mEGFP), to target the expression of the mEGFP to the

plasma membrane) or the equivalent forms of mEGFP linked to the C-terminal region of the monomeric, single transmembrane domain protein CD86 (Zakrys *et al.*, 2014, Ward *et al.*, 2015, Pediani *et al.*, 2016, Marsango *et al.*, 2017). For example, the analysis of the full data set obtained with the PM-mEGFP construct showed these to be distributed in Gaussian fashion with an MEU value very close to 1. This indicates that across the range of expression levels achieved, PM-mEGFP was routinely observed as being monomeric and that even at higher levels of expression it was not erroneously identified as being dimeric or oligomeric (Pediani *et al.*, 2016 and Marsango *et al.*, 2017).

The first class A GPCR to which this methodology was applied was the serotonin 5HT_{2C} receptor and it was found that the receptor existed as a complex mixture of oligomeric states from monomer to higher-order oligomers, with the most commonly found state being a dimer (Ward *et al.*, 2015). Interestingly, upon treatment with a number of receptor sub-type specific, but chemically distinct antagonists, this state was transformed into a predominantly monomeric one. Importantly for the potential pharmacological and, indeed clinical, relevance of these observations, washout of the drugs resulted in reformation of the original, complex oligomeric state, indicating the reversibility of the ligand effect (Ward *et al.*, 2015).

SpIDA has also been applied recently to study the effects of ligands on the quaternary structure of the M₁R (Pediani *et al.*, 2016). At the basolateral membrane of cells expressing an M₁R fused to monomeric enhanced green fluorescent protein (mEGFP), a 75%:25% mixture of M₁R monomers to M₁R dimers or higher-order oligomers was detected in the basal state (Pediani *et al.*, 2016). Upon treatment with the M₁R selective antagonist pirenzepine a large shift from the predominantly monomeric basal state, to a much more complex one containing receptor dimers and oligomers was observed (see **Figure 2**). A similar result was also produced by treatment with the chemically closely related M₁R selective antagonist telenzepine (Pediani *et al.*, 2016). However, this was not a general effect produced by all muscarinic antagonists. For example, neither atropine nor N-methylscopolamine (NMS), produced a change in M₁R oligomeric structure (Pediani *et al.*, 2016). Furthermore, although markedly selective for M₁R at higher concentrations both pirenzepine and

telenzepine can bind the M₃R. However, despite both being used at concentrations appropriate to their lower affinity at this receptor, neither antagonist was able to affect the organizational structure of the M₃R (Pediani *et al.*, 2016). This highlights that ligand regulation may be a receptor selective phenomenon and further studies to understand the molecular differences between M₁R and M₃R that result in this divergence should be illuminating. Notably, although not often quoted in reports on muscarinic receptor organization, earlier work by Ilein and collaborators (2009) had already noted that pirenzepine could promote M₁R dimerization. These studies indicated that rapid ligand binding to a site on the periphery of the receptor acts as a trigger for a series of conformational changes. These, in turn, were suggested to allow the ligand to access more deeply buried regions of the receptor, promoting the formation of high affinity dimers. An interesting corollary to this is the studies of Hern and collaborators (2010) who used a single molecule imaging technique, with a resolution of 20nm, known as total internal reflection fluorescence microscopy (TIRFM) to identify and track in real time individual M₁R molecules bound to (fluorescent) Cy3B-telenzepine. The receptors were found to be randomly distributed in the outer membrane of transfected CHO cells and at any given time 30% were in the form of dimers, in broad agreement with the work of Pediani and collaborators (2016).

Hern and collaborators (2010) considered “dimers” to be those tracks whose intensity was double that of the single fluorophore-ligand non-specifically bound to the glass slide. In more recent studies, the validity of receptor dimerization observed with TIRF analysis has been assessed using SNAP-tagged forms of CD86 (known to be monomeric) and comparing the intensity of its tracks with those measured for SNAP-SNAP-CD86 (Calebiro *et al.*, 2013) or SNAP-CD28 (known to be dimeric) (Tabor *et al.*, 2016).

SpIDA analysis on effects of ligands on muscarinic receptor organization has, to date, centred upon effects of antagonists. This reflects the potential for agonists to promote internalization of the receptor, and the approach requires analysis of receptors located at the cell surface. In the future, use of inhibitors that interfere with clathrin- or dynamin-mediated internalization may be useful. An alternative, and potentially more clear-cut approach, may be to employ genome-edited cells in which receptor internalization is blocked: e.g. using β -arrestin 1/2 knockout HEK293 cells (Alvarez-Curto *et al.*, 2016).

A number of studies have also examined the effects of muscarinic agonists as parts of wider studies on muscarinic oligomerization. For example, Herrick-Davis and collaborators (2013) made use of Fluorescence Correlation Spectroscopy (FCS) with photon counting histogram analysis to examine the oligomeric structure of a number of class A GPCRs including the M₁R and M₂R. These studies concluded that these receptors are exclusively dimeric and that treatment with the agonist carbachol had no effect upon this (Herrick-Davis *et al.*, 2013).

Finally, in a wide range of studies sustained treatment with antagonist ligands has resulted in upregulation of receptor levels and enhanced cell surface delivery. The muscarinic antagonist atropine has been found to increase expression and restore cell surface delivery of many of the mutants that Liste and collaborators generated and that showed the most impaired dimerization /oligomerization characteristics (Liste *et al.*, 2015). Interestingly, long term atropine treatment generally promoted enhanced organization of such mutants, with the majority showing a more similar organization to that of the wild-type receptor (Liste *et al.*, 2015). The role of so called molecular or pharmacological ‘chaperones’ has been widely discussed in the context of receptor trafficking and clearly can promote oligomeric organization at the cell surface. This is likely to be directly linked to early studies that centred on the role of receptor dimerization within the endoplasmic reticulum and the idea of oligomeric contacts as a key quality control points in the ontogeny of many GPCRs.

Conclusions and Future Perspectives

In this review, we have summarized current knowledge regarding the quaternary structure of the muscarinic acetylcholine receptor family by considering both of early work, particularly considering outcomes from ligand binding studies, and also results derived from more recently adopted approaches. For at least the M₁R-M₃R subtypes, where most work has been focussed, different and sometimes contradictory quaternary arrangements, have been described by various research groups. In this regard, it is important to mention that a large scale comparative study has just been published in which the quaternary structure of 60 class A rhodopsin-like GPCRs was analysed by BRET- and single-molecule microscopy-based assays (Felce *et al.*, 2017). The conclusion was that

only a small proportion of class A GPCRs (about 23%) forms authentic dimers while most of them, M₃R included, are present as monomers in HEK293 cells (Felce *et al.*, 2017).

Moreover, the authors concluded that dimers were formed from closely related phylogenetic clusters and that even closely related receptors could be organised in different quaternary structures (Felce *et al.*, 2017). Finally, the authors hypothesised that dimerization is an evolutionary process, one that increased the “fitness density” of those receptors, such as frizzled and glutamate, for which dimerization is essential for their function preventing them from diverging (Felce *et al.*, 2017). This was suggested to explain why dimerization, that does not confer functionality, is not a common feature among class A GPCRs (Felce *et al.*, 2017).

Similarly ligand binding to the receptors has been described as able, or not, to alter the quaternary arrangement of muscarinic receptors. However, despite this, the concept of class A GPCR oligomerization is one which has moved from the periphery of receptor biology to the mainstream. A great deal of extra study may be required before a coherent picture of the quaternary structure and physiological function of these receptors emerges and it is likely that further studies on muscarinic receptors will be involved in many aspects of this.

Acknowledgments

These studies were supported by grants from Medical Research Council (UK) [MR/L023806/1] and [G0900050] and Biotechnology and Biological Sciences Research Council [BB/E006302/1].

Technique	Receptor subtype/model system	Reference
Binding assays	M ₂ R; heart tissue M ₂ R; heart tissue M ₁ R; brain M ₂ R;M ₃ R heterologous system M ₂ R; phospholipid vesicles M ₂ R; phospholipid vesicles	Mattera et al., 1985 Galper et al., 1987 Potter et al., 1991 Maggio et al., 1999 Redka et al., 2013 Redka et al., 2014
Photo-affinity labelling	M ₁ R; brain	Avissar et al., 1983
Western blot/Co-Immunoprecipitation	M ₃ R; heterologous system M ₃ R; heterologous system M ₂ R; heterologous system M ₃ R; heterologous system M ₃ R; heterologous system M ₃ R; heterologous system M ₃ R; heterologous system	Wreggett and Wells, 1995 Zeng and Wess, 1999 Park and Wells, 2004 Hu et al., 2012 Hu et al., 2013 Liste et al., 2015 Pediani et al., 2016
BRET	M ₁ R, M ₂ R, M ₃ R; heterologous system M ₁ R; heterologous system M ₃ R; heterologous system	Goin and Nathanson, 2006 Marquer et al., 2010 McMillin et al., 2011
FRET/htrFRET	M ₃ R; heterologous system M ₂ R; heterologous system M ₃ R, M ₂ R; heterologous system M ₃ R; heterologous system M ₃ R; heterologous system	Alvarez-Curto et al., 2010a Pisterzi et al., 2010 Patowary et al., 2013 Aslanoglou et al., 2015 Liste et al., 2015
TIRF	M ₁ R; heterologous system M ₂ R; heart tissue and heterologous system	Hern et al., 2010 Nenasheva et al., 2013
SpIDA	M ₁ R, M ₃ R; heterologous system	Pediani et al., 2016
FCS	M ₁ R, M ₂ R; heterologous system	Herrick-Davis et al., 2013

Table 1. Summary of approaches used to detect dimers and/or higher-order oligomers of muscarinic receptor subtypes.

Figure 1 Quaternary organization of the hM₃R. (A) Representation of the four distinct low energy M₃R dimeric structures as described by McMillin and collaborators (2011). The transmembrane domains identified as being important for hM₃R protomer-protomer interactions are shown in *grey circles*. (Bi) Schematic representation of the quaternary arrangements of M₃R as described by Patowary and collaborators (2013). M₃R can form rhombic-shaped tetramers and dimers that are in equilibrium at the cell membrane. (Bii) Molecular model of the M₃R tetramer with a rhombic arrangement as a complex of two dimers represented as *grey and blue surfaces*. Predicted molecules of cholesterol are shown as *yellow spheres* (Figure adapted from Liste *et al.*, 2015).

Figure 2 Pirenzepine and telenzepine alter the quaternary structure of hM₁R, whilst atropine and NMS do not. The quaternary state of the hM₁R is shown in a graph in which the QB, presented as monomeric equivalent units (MEU), is plotted against the receptor expression level, presented as receptor per μm^2 , in cells not treated (*black circle*) or treated (*open circle*) with pirenzepine (A), telenzepine (B), atropine (C) or NMS (D). The percentage of RoIs characterized by the prevalence of hM₁R in monomeric (QB less than or equal to 1.274 (I)) and dimeric (QB bigger than 1.274 (II+)) state, in not treated (*black bars*) or antagonist treated (*open bars*) cells, is also indicated in the *insert*.

References

- Alvarez-Curto, E., Ward, R. J., Pediani, J. D. and Milligan, G. (2010a) Ligand Regulation of the Quaternary Organization of Cell Surface M3 Muscarinic Acetylcholine Receptors Analyzed by Fluorescence Resonance Energy Transfer (FRET) Imaging and Homogeneous Time-resolved FRET. *J. Biol. Chem.*, 285, 23318-23330. doi: 10.1074/jbc.M110.122184.
- Alvarez-Curto, E., Pediani, J.D., Milligan, G. (2010b) Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors. *Anal. Bioanal. Chem.* 398, 167-180. doi: 10.1007/s00216-010-3823-4.

Alvarez-Curto, E., Prihandoko, R., Tautermann, C.S., Zwier, J. M., Padiani, J. D., Lohse, M. J., Hoffmann, C., Tobin, A.B., Milligan, G. (2011) Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). *Mol. Pharmacol.* 80, 1033-1046. doi: 10.1124/mol.111.074674.

Alvarez-Curto, E., Inoue, A., Jenkins, L., Raihan, S. Z., Prihandoko, R., Tobin, A. B., Milligan, G. (2016) Targeted Elimination of G proteins and Arrestins Defines their Specific Contributions to both Intensity and Duration of G protein-Coupled Receptor Signalling. *J. Biol. Chem.* 291, 27147-27159. doi: 10.1074/jbc.M116.754887.

Aslanoglou, D., Alvarez-Curto, E., Marsango, S. and Milligan, G. (2015) Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers. *J. Biol. Chem.* 290, 14785-14796. doi: 10.1074/jbc.M115.649079.

Avissar, S., Amitai, G., Sokolovsky, M. (1983) Oligomeric structure of muscarinic receptors is shown by photoaffinity labeling: subunit assembly may explain high- and low-affinity agonist states. *Proc. Natl. Acad. Sci. U S A.* 80, 156-159.

Ayoub, M. A., Pflieger, K. D. (2010) Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. *Curr. Opin. Pharmacol.* 10, 44-52. doi: 10.1016/j.coph.2009.09.012.

Ayoub, M.A. (2016) Resonance Energy Transfer-Based Approaches to Study GPCRs. *Methods Cell Biol.* 132, 255-292. doi: 10.1016/bs.mcb.2015.10.008.

- Barbeau, A., Godin, A. G., Swift, J. L., De Koninck, Y., Wiseman, P. W., Beaulieu, J. M. (2013) Quantification of receptor tyrosine kinase activation and transactivation by G-protein-coupled receptors using spatial intensity distribution analysis (SpIDA). *Methods Enzymol.* 522, 109-131. doi: 10.1016/B978-0-12-408143-7.00001-3.
- Berrie, C. P. Birdsall, N. J., Burgen, A. S., Hulme, E. C. (1979) Guanine nucleotides modulate muscarinic receptor binding in the heart. *Biochem. Biophys. Res. Comm.* 87, 1000-1005
- Birdsall, N. J., Burgen, A. S., Hulme, E. C. (1978) The binding of agonists to brain muscarinic receptors. *Mol. Pharmacol.* 14, 723-736.
- Calebiro, D., Rieken, F., Wagner, J., Sungkaworn, T., Zabel, U., Borzi, A., Cocucci, E., Zürn, A., Lohse, M. J. (2013) Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. *Proc. Natl. Acad. Sci. U S A.* 110,743-748. doi: 10.1073/pnas.1205798110.
- Chabre, M., Cone, R., Saibil, H. (2003) Is rhodopsin dimeric in native retinal rods? *Nature.* 426, 30-31.
- Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., Stevens, R. C. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. *Science.* 318, 1258-1265.
- Ciruela, F., Vilardaga, J. P., Fernández-Dueñas, V. (2010) Lighting up multiprotein complexes: lessons from GPCR oligomerization. *Trends Biotechnol.* 28, 407-415. doi: 10.1016/j.tibtech.2010.05.002.

Conklin, B. R., Hsiao, E. C., Claeysen, S., Dumuis, A., Srinivasan, S., Forsayeth, J. R., Guettier, J. M., Chang, W. C., Pei, Y., McCarthy, K. D., Nissenson, R. A., Wess, J., Bockaert, J., Roth, B. L. (2008) Engineering GPCR signaling pathways with RASSLs. *Nat. Methods*. 5, 673-678. doi: 10.1038/nmeth.1232.

Dong, S., Rogan, S. C., Roth, B. L. (2010) Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. *Nat. Protoc.* 5, 561-573. doi: 10.1038/nprot.2009.239.

Ehlert, F. J. (1985) The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. *Mol. Pharmacol.* 28, 410-421

Farran, B. (2017) An update on the physiological and therapeutic relevance of GPCR oligomers. *Pharmacol. Res.* 117, 303-327. doi: 10.1016/j.phrs.2017.01.008.

Felce, J. H., Latty, S. L., Knox, R. G., Mattick, S. R., Lui, Y., Lee, S. F., Klenerman, D., Davis, S. J. (2017) Receptor Quaternary Organization Explains G Protein-Coupled Receptor Family Structure. *Cell Rep.* 20, 2654-2665. doi: 10.1016/j.celrep.2017.08.072.

Ferré, S., Casadó, V., Devi, L. A., Filizola, M., Jockers, R., Lohse, M. J., Milligan, G., Pin, J. P., Guitart, X. (2014) G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. *Pharmacol. Rev.* 66, 413-434. doi: 10.1124/pr.113.008052.

Fotiadis, D., Jastrzebska, B., Philippsen, A., Müller, D. J., Palczewski, K., Engel, A. (2006) Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. *Curr. Opin. Struct. Biol.* 16, 252-259.

Franco, R., Martinez-Pinilla, E., Lanciego, J. L., Navarro, G. (2016) Basic pharmacological and structural evidence for class A G-protein-coupled receptor heteromerisation. *Frontiers in Pharmacology*. 7, 76. doi: 10.3389/fphar.2016.00076.

Gahbauer, S, Böckmann, R. A. (2016) Membrane-mediated oligomerisation of G protein coupled receptors and its implications for GPCR function. *Frontiers in Pharmacology*. 7, 494: doi: 10.3389/fphar.2016.00494.

Galper, J. B., Haigh, L. S., Hart, A. C., O'Hara, D. S., Livingston, D. J. (1987) Muscarinic cholinergic receptors in the embryonic chick heart: interaction of agonist, receptor, and guanine nucleotides studied by an improved assay for direct binding of the muscarinic agonist [3H]cismethyldioxolane. *Mol. Pharmacol.* 32, 230-240.

Geng, Y., Mosyak, L., Kurinov, I., Zuo, H., Sturchler, E., Cheng, T. C., Subramanyam, P., Brown, A. P., Brennan S. C., Mun, H., Bush, M., Chen, Y., Nguyen, T. X., Cao, B., Chang, D. D., Quick, M., Conigrave, A. D., Colecraft, H. M., McDonald, P., Fan, Q. R. (2016) Structural mechanism of a ligand activation in human calcium-sensing receptor. *Elife*. 5. pii: e13662. doi: 10.7554/eLife.13662

Godin, A. G., Costantino, S., Lorenzo, L. E., Swift, J. L., Sergeev, M., Ribeiro-da-Silva, A., De Koninck, Y. and Wiseman, P. W. (2011) Revealing protein oligomerization and densities in situ using spatial intensity distribution analysis. *Proc. Natl. Acad. Sci. USA* 108, 7010-7015. doi: 10.1073/pnas.1018658108.

Godin, A. G., Rappaz, B., Potvin-Trottier, L., Kennedy, T. E., De Koninck, Y. and Wiseman, P.W. (2015) Spatial Intensity Distribution Analysis reveals abnormal oligomerization of proteins in single cells. *Biophys. J.* 109, 710-721. doi: 10.1016/j.bpj.2015.06.068.

Goin, J.C., Nathanson, N. M. (2006) Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells: regulation of receptor down-regulation by heterodimerization. *J. Biol. Chem.* 281, 5416-5425.

Gupta, K., Donlan, J. A. C., Hopper, J. T. S., Uzdavinyis, P., Landreh, M., Struwe, W. B., Drew, D., Baldwin, A. B., Stansfeld, P. J., Robinson, C. V. (2017) The role of interfacial lipids in stabilizing membrane protein oligomers. *Nature* 541, 421-424. doi: 10.1038/nature20820.

Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T., Kobayashi, T. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. *Nature*. 482, 547-551. doi: 10.1038/nature10753.

Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E. T., Lazareno, S., Molloy, J. E. and Birdsall, N. J. M. (2010) Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. *Proc. Natl. Acad. Sci. USA* 107, 2693-2698. doi: 10.1073/pnas.0907915107.

Herrick-Davis, K., Grinde, E., Cowan, A., Mazurkiewicz, J. E. (2013) Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. *Mol. Pharmacol.* 84, 630-642. doi: 10.1124/mol.113.087072.

Hirschberg, B. T., Schimerlik, M. I. (1994) A kinetic model for oxotremorine M binding to recombinant porcine m2 muscarinic receptors expressed in Chinese hamster ovary cells. *J. Biol. Chem.* 269, 26127-26135.

Hoffmann, C., Gaietta, G., Zürn, A., Adams, S. R., Terrillon, S., Ellisman, M. H., Tsien, R. Y., Lohse, M. J. (2010) Fluorescent labeling of tetracysteine-tagged proteins in intact cells. *Nat. Protoc.* 5, 1666-1677. doi: 10.1038/nprot.2010.129.

Hu, J., Thor, D., Zhou, Y., Liu, T., Wang, Y., McMillin, S. M., Mistry, R., Challiss, R.A., Costanzi, S., Wess, J. (2012) Structural aspects of M₃ muscarinic acetylcholine receptor dimer formation and activation. *FASEB J.* 26, 604-616. doi: 10.1096/fj.11-191510.

Hu, J., Hu, K., Liu, T., Stern, M. K., Mistry, R., Challiss, R. A., Costanzi, S., Wess, J. (2013) Novel structural and functional insights into M₃ muscarinic receptor dimer/oligomer formation. *J. Biol. Chem.* 288, 34777-34790. doi: 10.1074/jbc.M113.503714.

Huang, J., Chen, S., Zhang, J. J. and Huang, X.Y. (2013) Crystal structure of oligomeric β 1-adrenergic G protein-coupled receptors in ligand-free basal state. *Nat. Struct. Mol. Biol.* 20, 419-425. doi: 10.1038/nsmb.2504.

Hussain, A. F., Amoury, M., and Barth, S. (2013) SNAP-tag technology: A powerful tool for site specific conjugation of therapeutic and imaging agents. *Curr. Pharm. Des.* 19, 5437-5442.

Ilien, B., Glasser, N., Clamme, J. P., Didier, P., Piemont, E., Chinnappan, R., Daval, S. B., Galzi, J. L., Mely, Y. (2009) Pirenzepine promotes the dimerization of muscarinic M₁ receptors through a three-step binding process. *J. Biol. Chem.* 284, 19533-19543. doi: 10.1074/jbc.M109.017145.

Jaakola, V. P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y., Lane, J. R., Ijzerman, A. P., Stevens, R. C. (2008) The 2.6 angstrom crystal structure of a human A_{2A} adenosine receptor bound to an antagonist. *Science.* 322, 1211-1217. doi: 10.1126/science.1164772.

Jordan, B. A., Devi, L. A. (1999) G-protein-coupled receptor heterodimerisation modulates receptor function. *Nature* 399, 697-700.

Kniazeff, J., Prézeau, L., Rondard, P., Pin, J. P., Goudet C. Dimers and beyond: The functional puzzles of class C GPCRs. *Pharmacol. Ther.* 130, 9-25. doi: 10.1016/j.pharmthera.2011.01.006.

Kolberg, K., Puettmann, C., Pardo, A., Fitting, J., and Barth, S. (2013) SNAP-tag technology: a general introduction. *Curr. Pharm. Des.* 19, 5406–5413

Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., Kobilka, B. K. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. *Nature.* 482, 552-556. doi: 10.1038/nature10867.

Kruse, A. C., Kobilka, B. K., Gautam, D., Sexton, P. M., Christopoulos, A., Wess, J. (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. *Nat Rev Drug Discov.* 13, 549-60. doi: 10.1038/nrd4295. doi: 10.1038/nrd4295.

Kuner, R., Köhr, G., Grünewald, S., Eisenhardt, G., Bach, A., Kornau, H. C. (1999) Role of heteromer formation in GABAB receptor function. *Science.* 283, 74-77.

Kuzak, A.J., Pitchiaya, S., Anand, J.P., Mosberg, H.I., Walter, N.G., Sunahara, R.K. (2009) Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. *J. Biol. Chem.* 284, 26732-26741. doi: 10.1074/jbc.M109.026922.

Lane, J. R., Canals, M. (2012) Sequential conformational rearrangements dictate the dynamics of class C GPCR activation. *Science Signalling.* 5:pe51 doi: 10.1126/scisignal.2003503.

Liang, Y., Fotiadis, D., Filipek, S., Saperstein, D. A., Palczewski, K., Engel, A. (2003) Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. *J. Biol. Chem.* 278, 21655-21662.

Liste, M. J., Caltabiano, G., Ward, R. J., Alvarez-Curto, E., Marsango, S. and Milligan, G. (2015) The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor. *Mol. Pharmacol.* 87, 936-953. doi: 10.1124/mol.114.096925.

Maggio, R., Vogel, Z., Wess, J. (1993) Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. *Proc. Natl. Acad. Sci. U S A.* 90, 3103-3107.

Maggio, R., Barbier, P., Fornai, F., Corsini, G. U. (1996) Functional role of the third cytoplasmic loop in muscarinic receptor dimerization. *J. Biol. Chem.* 271, 31055-31060.

Maggio, R., Barbier, P., Colelli, A., Salvadori, F., Demontis, G., Corsini, G. U. (1999) G protein-linked receptors: pharmacological evidence for the formation of heterodimers. *J. Pharmacol. Exp. Ther.* 291, 251-257.

Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K. and Granier, S. (2012) Crystal structure of the μ -opioid receptor bound to a morphinan antagonist. *Nature* 485, 321-326. doi: 10.1038/nature10954.

Margeta-Mitrovic, M., Jan, Y. N., Jan, L.Y. (2000) A trafficking checkpoint controls GABA(B) receptor heterodimerization. *Neuron.* 27, 97-106.

Marquer, C., Fruchart-Gaillard, C., Mourier, G., Grandjean, O., Girard, E., le Maire, M., Brown, S., Servent, D. (2010) Influence of MT7 toxin on the oligomerization state of the M1 muscarinic receptor. *Biol. Cell.* 102, 409-420. doi: 10.1042/BC20090171.

Marsango, S., Caltabiano, G., Pou, C., Liste, M. J., Milligan, G. (2015a) Analysis of Human Dopamine D₃ Receptor Quaternary Structure. *J. Biol. Chem.* 290, 15146-15162. doi: 10.1074/jbc.M114.630681.

Marsango, S., Varela, M. J., Milligan, G. (2015b) Approaches to Characterize and Quantify Oligomerization of GPCRs. *Methods Mol. Biol.* 1335, 95-105. doi: 10.1007/978-1-4939-2914-6_7.

Marsango, S., Caltabiano, G., Jiménez-Rosés, M., Millan, M. J., Pediani, J. D., Ward, R. J. Milligan, G. (2017) A Molecular Basis for Selective Antagonist Destabilization of Dopamine D₃ Receptor Quaternary Organization. *Scientific Report*. Accepted for publication.

Mattera, R., Pitts, B. J., Entman, M. L., Birnbaumer, L. (1985) Guanine nucleotide regulation of a mammalian myocardial muscarinic receptor system. Evidence for homo- and heterotropic cooperativity in ligand binding analyzed by computer-assisted curve fitting. *J. Biol. Chem.* 260, 7410-7421.

Maurel, D., Comps-Agrar, L., Brock, C., Rives, M. L., Bourrier, E., Ayoub, M. A., Bazin, H., Tinel, N., Durroux, T., Prézeau, L., Trinquet, E., Pin, J. P. (2008) Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. *Nat. Methods.* 5, 561-567. doi: 10.1038/nmeth.1213.

McMillin, S. M., Heusel, M., Liu, T., Costanzi, S., Wess, J. (2011) Structural basis of M₃ muscarinic receptor dimer/oligomer formation. *J. Biol. Chem.* 286, 28584-28598. doi: 10.1007/978-1-4939-2914-6_7.

Miao, Y., Goldfeld, D. A., Von Moo, E., Sexton, P. M., Christopoulos, A., McCammon, J. A., Valant, C. (2016) Accelerated structure-based design of chemically diverse allosteric modulators of a

muscarinic G protein-coupled receptor. *Proc. Natl. Acad. Sci. U S A.* 113, E5675-5684. doi:

10.1073/pnas.1612353113.

Milligan, G. (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. *Mol. Pharm.* 66, 1-7.

Milligan, G. (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. *Br. J. Pharmacol.* 158, 5-14. doi: 10.1111/j.1476-5381.2009.00169.

Milligan, G. (2013) The prevalence, maintenance and relevance of G protein-coupled receptor oligomerisation. *Mol. Pharm.* 84, 158-169. doi: 10.1124/mol.113.084780.

Navarro, G., Cordomi, A., Zelman-Femiak, M., Burgarolas, M., Moreno, E., Aguinaga, D., Perez-Benito, L., Cortés, A., Casadó, V., Mallol, J., Canela, E. I., Lluis, C., Pardo, L., García-Sáez, A. J., McCormick, P. J., Franco, R. (2016) Quaternary structure of a G-protein-coupled receptor heterotrimer in complex with G_i and G_s. *BMC Biology.* 14, 26. doi 10.1186/s12915-016-0247-4.

Nenasheva, T. A., Neary, M., Mashanov, G. I., Birdsall, N. J., Breckenridge, R. A., Molloy, J. E. (2013) Abundance, distribution, mobility and oligomeric state of M₂ muscarinic acetylcholine receptors in live cardiac muscle. *J. Mol. Cell Cardiol.* 57, 129-136. doi: 10.1016/j.yjmcc.2013.01.009.

Ng, G. Y., Clark, J., Coulombe, N., Ethier, N., Hebert, T. E., Sullivan, R., Kargman, S., Chateaufneuf, A., Tsukamoto, N., McDonald, T., Whiting, P., Mezey, E., Johnson, M. P., Liu, Q., Kolakowski, L. F. Jr, Evans, J. F., Bonner, T. I., O'Neill, G. P. (1999) Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. *J. Biol. Chem.* 274, 7607-7610.

- Ng, G.Y., Bertrand, S., Sullivan, R., Ethier, N., Wang, J., Yergey, J., Belley, M., Trimble, L., Bateman, K., Alder, L., Smith, A., McKernan, R., Metters, K., O'Neill, G. P., Lacaille, J. C., Hébert, T. E. (2001) Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. *Mol. Pharmacol.* 59, 144-152.
- Patowary, S., Alvarez-Curto, E., Xu, T.R., Holz, J.D., Oliver, J.A., Milligan, G. and Raicu, V. (2013) The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. *Biochem. J.* 452, 303-312. doi: 10.1042/BJ20121902.
- Park, P. S. and Wells, J. W. (2004) Oligomeric potential of the M2 muscarinic cholinergic receptor. *J. Neurochem.* 90, 537-548.
- Pediani, J. D., Ward, R. J., Godin, A. G., Marsango, S., Milligan, G. (2016) Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs. *J. Biol. Chem.* 291, 13132-13146. doi: 10.1074/jbc.M115.712562.
- Pediani, J. D., Ward, R. J., Marsango, S., Milligan, G. (2017) Spatial Intensity Distribution Analysis: Studies of G Protein-Coupled Receptor Oligomerisation. *Trends Pharmacol Sci.* 1465, 30180-30183. doi: 10.1016/j.tips.2017.09.001.
- Pei, Y., Rogan, S. C., Yan, F., Roth, B. L. (2008) Engineered GPCRs as tools to modulate signal transduction. *Physiology (Bethesda)*. 23, 313-321. doi: 10.1152/physiol.00025.2008.
- Pisterzi, L. F., Jansma, D. B., Georgiou, J., Woodside, M. J., Chou, J. T., Angers, S., Raicu, V., Wells, J.W. (2010) Oligomeric size of the m2 muscarinic receptor in live cells as determined by quantitative

fluorescence resonance energy transfer. *J. Biol. Chem.* 285, 16723-16738. doi:

10.1074/jbc.M109.069443.

Potter, L. T., Ballesteros, L. A., Bichajian, L. H., Ferrendelli, C. A., Fisher, A., Hanchett, H. E.,

Zhang, R. (1991) Evidence of paired M2 muscarinic receptors. *Mol. Pharmacol.* 39, 211-221.

Rasmussen, S. G., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S.,

Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T., Lyons, J. A., Caffrey, M.,

Gellman, S. H., Steyaert, J., Skinioitis, G., Weis, W. I., Sunahara, R. K., Kobilka, B. K. (2011) Crystal

structure of the β_2 adrenergic receptor-Gs protein complex. *Nature.* 477, 549-555. doi:

10.1038/nature10361.

Redka, D. S., Heerklotz, H., Wells, J. W. (2013) Efficacy as an intrinsic property of the M(2)

muscarinic receptor in its tetrameric state. *Biochemistry.* 52, 7405-7427. doi: 10.1021/bi4003869.

Redka, D. S., Morizumi, T., Elmslie, G., Paranthaman, P., Shivnaraine, R. V., Ellis, J., Ernst, O.P.,

Wells, J. W. (2014) Coupling of g proteins to reconstituted monomers and tetramers of the M2

muscarinic receptor. *J. Biol. Chem.* 289, 24347-24365. doi: 10.1074/jbc.M114.559294.

Shivnaraine, R. V., Fernandes, D. D., Ji, H., Li, Y., Kelly, B., Zhang, Z., Han, Y. R., Huang, F.,

Sankar, K. S., Dubins, D. N., Rocheleau, J. V., Wells, J. W., Gradinaru, C. C. (2016a) Single-

Molecule Analysis of the Supramolecular Organization of the M2 Muscarinic Receptor and the G α 1

Protein. *J. Am. Chem. Soc.* 138, 11583-11598. doi: 10.1021/jacs.6b04032.

Shivnaraine, R. V., Kelly, B., Sankar, K. S., Redka, D. S., Han, Y. R., Huang, F., Elmslie, G., Pinto,

D., Li, Y., Rocheleau, J. V., Gradinaru, C. C., Ellis, J., Wells, J. W. (2016b) Allosteric modulation in

monomers and oligomers of a G protein-coupled receptor. *Elife.* 6;5: pii: e11685. doi:

10.7554/eLife.11685.

Smith, N. J., Milligan, G. (2010) Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. *Pharmacol. Rev.* 62, 701-725. doi: 10.1124/pr.110.002667.

Sposini, S., Caltabiano, G., Hanyaloglu, A. C., Miele, R. (2015) Identification of transmembrane domains that regulate spatial arrangements and activity of prokineticin receptor 2 dimers. *Mol. Cell. Endocrinol.* 399, 362-372. doi: 10.1016/j.mce.2014.10.024.

Suda, K., Filipek, S., Palczewski, K., Engel, A., Fotiadis, D. (2004) The supramolecular structure of the GPCR rhodopsin in solution and native disc membranes. *Mol. Membr. Biol.* 21, 435-446.

Szalai, B., Barkai, L., Turu, G., Szidonya, L., Várnai, P., Hunyady, L. (2012) Allosteric interactions within the AT₁ angiotension receptor homodimer: Role of the conserved DRY motif. *Biochem. Pharma.* 84, 477-485. doi: 10.1016/j.bcp.2012.04.014.

Tabor, A., Weisenburger, S., Banerjee, A., Purkayastha, N., Kaindl, J. M., Hübner, H., Wei, L., Grömer, T. W., Kornhuber, J., Tschammer, N., Birdsall, N. J., Mashanov, G. I., Sandoghdar, V., Gmeiner, P. (2016) Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level. *Sci. Rep.* 6, 33233. doi: 10.1038/srep33233.

Thal, D. M., Sun, B., Feng, D., Nawaratne, V., Leach, K., Felder, C. C., Bures, M. G., Evans D. A., Weis, W. I., Bachhawat, P., Kobilka, T. S., Sexton, P. M., Kobilka, B. K., Christopoulos, A. (2016) Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. *Nature.* 531, 335-340. doi: 10.1038/nature17188.

Vafabakhsh, R., Levitz, J., Isacoff, E. Y. (2015) Conformational dynamics of a class C G-protein-coupled receptor. *Nature* 524, 497-501. doi: 10.1038/nature14679.

Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L., Stevens, R. C. (2013) Structural features for functional selectivity at serotonin receptors. *Science*. 340, 615-619. doi: 10.1126/science.1232808.

Ward, R. J., Pediani, J. D. and Milligan, G. (2010) Ligand-induced internalisation of the orexin OX₁ and cannabinoid CB₁ receptors assessed via N-terminal SNAP and CLIP-tagging. *Br. J. Pharm.* 162, 1439-1452. doi: 10.1111/j.1476-5381.2010.01156.

Ward, R. J., Pediani, J. D., Godin, A. G. and Milligan, G. (2015) Regulation of oligomeric organization of the serotonin 5-hydroxytryptamine 2C (5-HT_{2C}) receptor observed by spatial intensity distribution analysis. *J. Biol. Chem.* 290, 12844-12857. doi: 10.1074/jbc.M115.644724.

Ward, R. J., Pediani, J. D., Harikumar, K. G., Miller, L. J. and Milligan, G. (2017) Spatial Intensity Distribution Analysis quantifies the extent and regulation of homo-dimerization of the secretin receptor. *Biochem. J.* 474, 1879-1895. doi: 10.1042/BCJ20170184.

Whorton, M.R., Bokoch, M.P., Rasmussen, S.G.F., Huang, B., Zare, R.N., Kobilka, B, Sunahara, R.K. (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. *Proc. Natl. Acad. Sci. USA.* 104, 7682-7687.

Wreggett, K. A., Wells, J. W. (1995) Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. *J. Biol. Chem.* 270, 22488-22499.

Zakrys, L., Ward, R. J., Pediani, J. D., Godin, A. G., Graham, G. J. and Milligan, G. (2014).


Roundabout 1 exists predominantly as a basal dimeric complex and this is unaffected by binding of the ligand Slit2. *Biochem. J.* 461, 61-73. doi: 10.1042/BJ20140190.

Zeng, F. Y., Wess, J. (1999) Identification and molecular characterization of m3 muscarinic receptor dimers. *J. Biol. Chem.* 274, 19487-19497.


Zhang, K., Zhang, J., Gao, Z. G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paoletta, S., Kiselev, E., Lu, W., Fenalti, G., Zhang, W., Müller, C. E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K. A., Stevens, R. C., Wu, B., Zhao, Q. (2014) Structure of the human P2Y12 receptor in complex with an antithrombotic drug. *Nature*. 509, 115-118. doi: 10.1038/nature13083.

Figure 1


A




TMV-TMV



TMVI-TMVII




TMIV-TMV



TMI-TMII

B i




Rhombic shape tetramer



Dimers


ii



Rhombic shape tetramer
 dimer(TMI-II HelixVIII)+dimer(TMI-II HelixVIII)

ACCEPTED MANUSCRIPT

Figure 2



Muscarinic receptor oligomerization**Sara Marsango, Richard J. Ward, Elisa Alvarez-Curto and Graeme Milligan**

Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ
Scotland, U.K.

Address correspondence to Sara Marsango (Sara.Marsango@glasgow.ac.uk) or Richard J. Ward (Richard.Ward@glasgow.ac.uk)

Highlights

- Muscarinic acetylcholine receptors are GPCRs expressed in the nervous systems
- These receptors can function as monomers and also form dimers and oligomers
- A broad range of approaches have been employed to study their quaternary structure
- The main outcomes obtained from over 30 years of work are discussed here